Skip to main content

Table 1 Patient demographics and baseline clinical characteristics[8]

From: Multivariate and subgroup analyses of a randomized, multinational, phase 3 trial of decitabine vs treatment choice of supportive care or cytarabine in older patients with newly diagnosed acute myeloid leukemia and poor- or intermediate-risk cytogenetics

Parameter Total TC (n = 243) Decitabine (n = 242)
Median age, years (range) 73.0 (64.0–91.0) 73.0 (64.0–89.0)
 <70 years 70 (28.8) 71 (29.3)
 70–74 years 74 (30.5) 76 (31.4)
 ≥75 years 99 (40.8) 95 (39.3)
Sex, n (%)
 Female 92 (37.9) 105 (43.4)
 Male 151 (62.1) 137 (56.6)
Median BSA, m2 (range) 1.80 (1.3–2.7) 1.82 (1.4–2.6)
Median time since AML diagnosis, days (range) 15.0 (0–398.0) 14.0 (3.0–346.0)
Type of AML, n (%)
 De novo 157 (64.6) 155 (64.0)
 Secondary 84 (34.6) 87 (36.0)
Bone marrow blasts, n (%)
 <20% 8 (3.3) 4 (1.7)
 20%–30% 58 (24.1) 65 (27.0)
 >30%–50% 74 (30.7) 67 (27.8)
 >50% 101 (41.9) 105 (43.7)
ECOG PS, n (%)
 0 or 1 178 (73.2) 182 (75.3)
 2 65 (26.7) 60 (24.8)
Cytogenetics, n (%)
 Intermediate risk 154 (63.6) 152 (63.1)
 Poor risk 87 (36.0) 87 (36.1)
Median hemoglobin, g/dL (range) 9.4 (5.0–12.6) 9.3 (5.2–15.0)
Platelets, n 213 225
 Median, 109/L (range) 50.00 (6.0–490.0) 58.00 (6.0–487.0)
White blood cells, n 236 237
 Median, 109/L (range) 3.69 (0.5–80.9) 3.10 (0.3–127.0)
  1. AML, acute myeloid leukemia; ECOG PS, Eastern Cooperative Oncology Group Performance Status; TC, treatment choice, with physician’s advice.